Top

Published in:

01-06-2016 | Editorial

Adrenoceptor modulators and cancer progression

Author: Kazuyoshi Hirota

Published in: Journal of Anesthesia | Issue 3/2016

Excerpt

Several recent articles published in the Journal of Anesthesia suggest that anesthetic agents, sedatives, and opioids may affect cancer relapse, metastasis, and recurrence [1‐3]. In addition, we use adrenoceptor agonists or antagonists in the perioperative setting for hemodynamic maintenance in patients undergoing radical cancer surgery. Moreover, the highly selective α2-agonist dexmedetomidine is often used as a sedative in the intensive care unit and sometimes as an adjuvant in paravertebral block to reduce postoperative opioid consumption and the incidence of nausea and vomiting [4]. However, do we know whether these agents affect prognosis in cancer patients? In this editorial, effects of adrenoceptor modulators on cancer are discussed. …

Niwa H, Rowbotham DJ, Lambert DG, Buggy DJ. Can anesthetic techniques or drugs affect cancer recurrence in patients undergoing cancer surgery? J Anesth. 2013;27:731–41.CrossRefPubMed

Nomura Y, Kawaraguchi Y, Sugimoto H, Furuya H, Kawaguchi M. Effects of morphine and fentanyl on 5-fluorouracil sensitivity in human colon cancer HCT116 cells. J Anesth. 2014;28:298–301.CrossRefPubMed

Nishiwada T, Kawaraguchi Y, Uemura K, Sugimoto H, Kawaguchi M. Effect of sevoflurane on human hepatocellular carcinoma HepG2 cells under conditions of high glucose and insulin. J Anesth. 2015;29:805–8.CrossRefPubMed

Mohta M, Kalra B, Sethi AK, Kaur N. Efficacy of dexmedetomidine as an adjuvant in paravertebral block in breast cancer surgery. J Anesth. 2016;30:252–60.CrossRefPubMed

Cole SW, Sood AK. Molecular pathways: beta-adrenergic signaling in cancer. Clin Cancer Res. 2012;18:1201–6.CrossRefPubMedPubMedCentral

Tang J, Li Z, Lu L, Lu L, Cho CH. β-Adrenergic system, a backstage manipulator regulating tumour progression and drug target in cancer therapy. Semin Cancer Biol. 2013;23:533–42.CrossRefPubMed

Stiles JM, Amaya C, Rains S, Diaz D, Pham R, Battiste J, Modiano JF, Kokta V, Boucheron LE, Mitchell DC, Bryan BA. Targeting of beta adrenergic receptors results in therapeutic efficacy against models of hemangioendothelioma and angiosarcoma. PLoS One. 2013;8:e60021.CrossRefPubMedPubMedCentral

De Giorgi V, Gandini S, Grazzini M, Benemei S, Marchionni N, Geppetti P. Effect of β-blockers and other antihypertensive drugs on the risk of melanoma recurrence and death. Mayo Clin Proc. 2013;88:1196–203.CrossRefPubMed

McCourt C, Coleman HG, Murray LJ, Cantwell MM, Dolan O, Powe DG, Cardwell CR. β-Blocker usage after malignant melanoma diagnosis and survival: a population-based nested case-control study. Br J Dermatol. 2014;170:930–8.CrossRefPubMed

10.

Heitz F, du Bois A, Harter P, Lubbe D, Kurzeder C, Vergote I, Plante M, Pfisterer J, AGO study group; NCIC-CTG study group; EORTC-GCG study group. Impact of beta blocker medication in patients with platinum sensitive recurrent ovarian cancer: a combined analysis of two prospective multicenter trials by the AGO Study Group, NCIC-CTG and EORTC-GCG. Gynecol Oncol. 2013;129:463–6.CrossRefPubMed

11.

Jansen L, Below J, Chang-Claude J, Brenner H, Hoffmeister M. Beta blocker use and colorectal cancer risk: population-based case-control study. Cancer (Phila). 2012;118:3911–9.CrossRef

12.

Sørensen GV, Ganz PA, Cole SW, Pedersen LA, Sørensen HT, Cronin-Fenton DP, Garne JP, Christiansen PM, Lash TL, Ahern TP. Use of β-blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and risk of breast cancer recurrence: a Danish nationwide prospective cohort study. J Clin Oncol. 2013;31:2265–72.CrossRefPubMedPubMedCentral

13.

Livingstone E, Hollestein LM, van Herk-Sukel MP, van de Poll-Franse L, Nijsten T, Schadendorf D, de Vries E. β-Blocker use and all-cause mortality of melanoma patients: results from a population-based Dutch cohort study. Eur J Cancer. 2013;49:3863–71.CrossRefPubMed

14.

Hicks BM, Murray LJ, Powe DG, Hughes CM, Cardwell CR. β-Blocker usage and colorectal cancer mortality: a nested case-control study in the UK Clinical Practice Research Datalink cohort. Ann Oncol. 2013;24:3100–6.CrossRefPubMed

15.

Cata JP, Villarreal J, Keerty D, Thakar DR, Liu DD, Sood AK, Gottumukkala V. Perioperative β-blocker use and survival in lung cancer patients. J Clin Anesth. 2014;26:106–17.CrossRefPubMed

16.

Cardwell CR, Coleman HG, Murray LJ, Entschladen F, Powe DG. Beta-blocker usage and breast cancer survival: a nested case-control study within a UK clinical practice research datalink cohort. Int J Epidemiol. 2013;42:1852–61.CrossRefPubMed

17.

Nkontchou G, Aout M, Mahmoudi A, Roulot D, Bourcier V, Grando-Lemaire V, Ganne-Carrie N, Trinchet JC, Vicaut E, Beaugrand M. Effect of long-term propranolol treatment on hepatocellular carcinoma incidence in patients with HCV-associated cirrhosis. Cancer Prev Res (Phila). 2012;5:1007–14.CrossRef

18.

Monami M, Filippi L, Ungar A, Sgrilli F, Antenore A, Dicembrini I, Bagnoli P, Marchionni N, Rotella CM, Mannucci E. Further data on beta-blockers and cancer risk: observational study and meta-analysis of randomized clinical trials. Curr Med Res Opin. 2013;29:369–78.CrossRefPubMed

19.

Katsogiannou M, El Boustany C, Gackiere F, Delcourt P, Athias A, Mariot P, Dewailly E, Jouy N, Lamaze C, Bidaux G, Mauroy B, Prevarskaya N, Slomianny C. Caveolae contribute to the apoptosis resistance induced by the α(1A)-adrenoceptor in androgen-independent prostate cancer cells. PLoS One. 2009;4:e7068.CrossRefPubMedPubMedCentral

20.

Hori Y, Ishii K, Kanda H, Iwamoto Y, Nishikawa K, Soga N, Kise H, Arima K, Sugimura Y. Naftopidil, a selective α1-adrenoceptor antagonist, suppresses human prostate tumor growth by altering interactions between tumor cells and stroma. Cancer Prev Res (Phila). 2011;4:87–96.CrossRef

21.

Yamada D, Nishimatsu H, Kumano S, Hirano Y, Suzuki M, Fujimura T, Fukuhara H, Enomoto Y, Kume H, Homma Y. Reduction of prostate cancer incidence by naftopidil, an α1-adrenoceptor antagonist and transforming growth factor-β signaling inhibitor. Int J Urol. 2013;20:1220–7.CrossRefPubMed

22.

Masachika E, Kanno T, Nakano T, Gotoh A, Nishizaki T. Naftopidil induces apoptosis in malignant mesothelioma cell lines independently of α1-adrenoceptor blocking. Anticancer Res. 2013;33:887–94.PubMed

23.

Fuchs R, Schwach G, Stracke A, Meier-Allard N, Absenger M, Ingolic E, Haas HS, Pfragner R, Sadjak A. The anti-hypertensive drug prazosin induces apoptosis in the medullary thyroid carcinoma cell line TT. Anticancer Res. 2015;35:31–8.PubMedPubMedCentral

24.

Bruzzone A, Piñero CP, Rojas P, Romanato M, Gass H, Lanari C, Lüthy IA. α2-Adrenoceptors enhance cell proliferation and mammary tumor growth acting through both the stroma and the tumor cells. Curr Cancer Drug Targets. 2011;11:763–74.CrossRefPubMed

25.

Lamkin DM, Sung HY, Yang GS, David JM, Ma JC, Cole SW, Sloan EK. α2-Adrenergic blockade mimics the enhancing effect of chronic stress on breast cancer progression. Psychoneuroendocrinology. 2015;51:262–70.CrossRefPubMedPubMedCentral

26.

Griwan MS, Karthikeyan YR, Kumar M, Singh BJ, Singh SK. Comparative evaluation of naftopidil and tamsulosin in the treatment of patients with lower urinary tract symptoms with benign prostatic hyperplasia. Urol Ann. 2014;6:181–6.CrossRefPubMedPubMedCentral

27.

Huang J, He F, Huang M, Liu X, Xiong Y, Huang Y, Zhu L, Yang Y, Xu X, Yuan M. Novel naftopidil-related derivatives and their biological effects as alpha1-adrenoceptors antagonists and antiproliferative agents. Eur J Med Chem. 2015;96:83–91.CrossRefPubMed

28.

Bruzzone A, Piñero CP, Castillo LF, Sarappa MG, Rojas P, Lanari C, Lüthy IA. Alpha-2-adrenoceptor action on cell proliferation and mammary tumour growth in mice. Br J Pharmacol. 2008;155:494–504.CrossRefPubMedPubMedCentral

29.

Shkurnikov MY, Galatenko VV, Lebedev AE, Podol’skii VE, Tonevitskii EA, Mal’tseva DV. On statistical relationship between ADRA2A expression and the risk of breast cancer relapse. Bull Exp Biol Med. 2014;157:454–8.CrossRefPubMed

30.

31.

Szpunar MJ, Burke KA, Dawes RP, Brown EB, Madden KS. The antidepressant desipramine and α2-adrenergic receptor activation promote breast tumor progression in association with altered collagen structure. Cancer Prev Res (Phila). 2013;6:1262–72.CrossRef

32.

Levy I, Horvath A, Azevedo M, de Alexandre RB, Stratakis CA. Phosphodiesterase function and endocrine cells: links to human disease and roles in tumor development and treatment. Curr Opin Pharmacol. 2011;11:689–97.CrossRefPubMedPubMedCentral

Title: Adrenoceptor modulators and cancer progression
Author: Kazuyoshi Hirota
Publication date: 01-06-2016
Publisher: Springer Japan
Published in: Journal of Anesthesia / Issue 3/2016
Print ISSN: 0913-8668
Electronic ISSN: 1438-8359
DOI: https://doi.org/10.1007/s00540-016-2171-8

At a glance: The STEP trials

Springer Medicine

Adrenoceptor modulators and cancer progression

Excerpt

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 3/2016

A case of mutism on emergence from general anesthesia

Blood transfusion, colloid therapy and the possible saving of albumin volumes during surgery: data analysis of the survey for certified hospitals of the Japanese Society of Anesthesiologists

Pillow height for i-gel® insertion: a randomized clinical trial

Propofol reduces liver dysfunction caused by tumor necrosis factor-α production in Kupffer cells

Remifentanil: applications in neonates

Impact of anesthetic technique on the stress response elicited by laparoscopic cholecystectomy: a randomized trial